162 related articles for article (PubMed ID: 12056551)
1. Nonpeptidic endothelin-converting enzyme inhibitors and their potential therapeutic applications.
Jeng AY; Mulder P; Kwan AL; Battistini B
Can J Physiol Pharmacol; 2002 May; 80(5):440-9. PubMed ID: 12056551
[TBL] [Abstract][Full Text] [Related]
2. Utility of endothelin-converting enzyme inhibitors for the treatment of cardiovascular diseases.
Jeng AY
Curr Opin Investig Drugs; 2003 Sep; 4(9):1076-81. PubMed ID: 14582451
[TBL] [Abstract][Full Text] [Related]
3. Endothelin-converting enzyme inhibitors for the treatment of subarachnoid hemorrhage-induced vasospasm.
Lin CL; Winardi W; Jeng AY; Kwan AL
Neurol Res; 2006 Oct; 28(7):721-9. PubMed ID: 17164035
[TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of potent, selective inhibitors of endothelin-converting enzyme.
Wallace EM; Moliterni JA; Moskal MA; Neubert AD; Marcopulos N; Stamford LB; Trapani AJ; Savage P; Chou M; Jeng AY
J Med Chem; 1998 Apr; 41(9):1513-23. PubMed ID: 9554884
[TBL] [Abstract][Full Text] [Related]
5. CGS 34226, a thiol-based dual inhibitor of endothelin converting enzyme-1 and neutral endopeptidase 24.11.
Jeng AY; Savage P; Beil ME; Bruseo CW; Hoyer D; Fink CA; Trapani AJ
Clin Sci (Lond); 2002 Aug; 103 Suppl 48():98S-101S. PubMed ID: 12193064
[TBL] [Abstract][Full Text] [Related]
6. Endothelin-converting enzyme-1 inhibition and renoprotection in end-stage renal disease.
Kuruppu S; Rajapakse NW; Smith AI
Pflugers Arch; 2013 Jul; 465(7):929-34. PubMed ID: 23328864
[TBL] [Abstract][Full Text] [Related]
7. Endothelin and subarachnoid hemorrhage-induced cerebral vasospasm: pathogenesis and treatment.
Lin CL; Jeng AY; Howng SL; Kwan AL
Curr Med Chem; 2004 Jul; 11(13):1779-91. PubMed ID: 15279581
[TBL] [Abstract][Full Text] [Related]
8. CGS 35601, a triple inhibitor of angiotensin converting enzyme, neutral endopeptidase and endothelin converting enzyme.
Battistini B; Daull P; Jeng AY
Cardiovasc Drug Rev; 2005; 23(4):317-30. PubMed ID: 16614731
[TBL] [Abstract][Full Text] [Related]
9. Benzofused macrocyclic lactams as triple inhibitors of endothelin-converting enzyme, neutral endopeptidase 24.11, and angiotensin-converting enzyme.
Ksander GM; Savage P; Trapani AJ; Balwierczak JL; Jeng AY
J Cardiovasc Pharmacol; 1998; 31 Suppl 1():S71-3. PubMed ID: 9595404
[TBL] [Abstract][Full Text] [Related]
10. Potent and selective non-peptidic inhibitors of endothelin-converting enzyme-1 with sustained duration of action.
De Lombaert S; Blanchard L; Stamford LB; Tan J; Wallace EM; Satoh Y; Fitt J; Hoyer D; Simonsbergen D; Moliterni J; Marcopoulos N; Savage P; Chou M; Trapani AJ; Jeng AY
J Med Chem; 2000 Feb; 43(3):488-504. PubMed ID: 10669576
[TBL] [Abstract][Full Text] [Related]
11. Structure of human endothelin-converting enzyme I complexed with phosphoramidon.
Schulz H; Dale GE; Karimi-Nejad Y; Oefner C
J Mol Biol; 2009 Jan; 385(1):178-87. PubMed ID: 18992253
[TBL] [Abstract][Full Text] [Related]
12. Towards triple vasopeptidase inhibitors for the treatment of cardiovascular diseases.
Daull P; Jeng AY; Battistini B
J Cardiovasc Pharmacol; 2007 Sep; 50(3):247-56. PubMed ID: 17878751
[TBL] [Abstract][Full Text] [Related]
13. Differential structure-activity relationships of phosphoramidon analogues for inhibition of three metalloproteases: endothelin-converting enzyme, neutral endopeptidase, and angiotensin-converting enzyme.
Kukkola PJ; Savage P; Sakane Y; Berry JC; Bilci NA; Ghai RD; Jeng AY
J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S65-8. PubMed ID: 8587470
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of neointima formation in an organ culture of human saphenous vein: a comparison of dual endothelin-converting enzyme/neutral endopeptidase and selective neutral endopeptidase inhibition.
Porter KE; Dickinson T; London NJ
J Vasc Surg; 2001 Sep; 34(3):548-54. PubMed ID: 11533610
[TBL] [Abstract][Full Text] [Related]
15. CGS 34043: a non-peptidic, potent and long-acting dual inhibitor of endothelin converting enzyme-1 and neutral endopeptidase 24.11.
Trapani AJ; De Lombaert S; Beil ME; Bruseo CW; Savage P; Chou M; Jeng AY
Life Sci; 2000; 67(9):1025-33. PubMed ID: 10954036
[TBL] [Abstract][Full Text] [Related]
16. Triple ACE-ECE-NEP inhibition in heart failure: a comparison with ACE and dual ECE-NEP inhibition.
Mellin V; Jeng AY; Monteil C; Renet S; Henry JP; Thuillez C; Mulder P
J Cardiovasc Pharmacol; 2005 Sep; 46(3):390-7. PubMed ID: 16116347
[TBL] [Abstract][Full Text] [Related]
17. Effects of the ECE/NEP inhibitor CGS 34225 on the big ET-1-induced pressor response and plasma atrial natriuretic peptide concentration in conscious rats.
Trapani AJ; Beil ME; Bruseo CW; Fink CA; Hoyer D; Savage P; Jeng AY
Clin Sci (Lond); 2002 Aug; 103 Suppl 48():102S-106S. PubMed ID: 12193065
[TBL] [Abstract][Full Text] [Related]
18. Endothelin-converting enzyme/neutral endopeptidase inhibitor SLV338 prevents hypertensive cardiac remodeling in a blood pressure-independent manner.
Kalk P; Sharkovska Y; Kashina E; von Websky K; Relle K; Pfab T; Alter M; Guillaume P; Provost D; Hoffmann K; Fischer Y; Hocher B
Hypertension; 2011 Apr; 57(4):755-63. PubMed ID: 21339476
[TBL] [Abstract][Full Text] [Related]
19. The therapeutic potential of endothelin-1 receptor antagonists and endothelin-converting enzyme inhibitors on the cardiovascular system.
Doggrell SA
Expert Opin Investig Drugs; 2002 Nov; 11(11):1537-52. PubMed ID: 12437501
[TBL] [Abstract][Full Text] [Related]
20. Renoprotective effects of combined endothelin-converting enzyme/neutral endopeptidase inhibitor SLV338 in acute and chronic experimental renal damage.
Sharkovska Y; Kalk P; von Websky K; Relle K; Pfab T; Alter M; Fischer Y; Hocher B
Clin Lab; 2011; 57(7-8):507-15. PubMed ID: 21888014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
